{"id":57864,"date":"2024-08-01T12:04:23","date_gmt":"2024-08-01T12:04:23","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/08\/01\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/"},"modified":"2024-08-01T12:04:23","modified_gmt":"2024-08-01T12:04:23","slug":"spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/","title":{"rendered":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease"},"content":{"rendered":"<div>\n<p><em>SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer\u2019s disease<\/em><\/p>\n<p align=\"left\">LOS ANGELES, Aug.  01, 2024  (GLOBE NEWSWIRE) &#8212; Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that enrollment is now open in Australia for their Phase 2 clinical trial evaluating SPG302 for the treatment of people with Alzheimer\u2019s disease (AD), the most prevalent form of dementia worldwide.<\/p>\n<p>\u201cThe SPG302 trials are a completely different approach to tackling Alzheimer\u2019s Disease,\u201d stated Bruce Brew, MD, DSc, FRACP, FAAN, neurologist and trial Principal Investigator at St. Vincent\u2019s Hospital in Sydney, Australia. \u201cUnlike other approaches, SPG302 has the prospect for some degree of regeneration and consequent improvement in memory, instead of just slowing the disease. This is a refreshing, long-awaited and cutting-edge approach to the disease,\u00a0if it\u2019s successful, it could be the dawn of a new era in treating Alzheimer\u2019s disease.\u201d<\/p>\n<p>\u201cThere are currently no approved drugs for Alzheimer\u2019s disease that focus on restoring function to reverse the course of disease by targeting the synapses. At Spinogenix, our mission is to offer new hope to people battling AD, not just by slowing the disease but by potentially reversing it, offering a significant departure from conventional approaches\u201d said Stella Sarraf, Ph.D., Spinogenix Chief Executive Officer and Founder.<\/p>\n<p>The Phase 2 trial will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of a once-a day pill of SPG302 in adult participants with mild-to-moderate Alzheimer\u2019s disease. Enrollment is currently open at St. Vincents Hospital, Sydney, NSW, Australia with plans for a second site opening soon at Flinders Medical Center, Adelaide, SA, Australia. Additional information is available on ClinicalTrials.gov (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vS-Y_KNInJmZrdROP-l79BzQvW5lQZ8eU8LKIQ0ijfc0pECdL3MeYRYXY-Vo4h7TD6BCm2QIPlcWWUHdMw7dB7Cbg1Mb9i925jPgJpZazRg=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"NCT06427668\">NCT06427668<\/a>).<\/p>\n<p>SPG302 is also being evaluated in Amyotrophic lateral sclerosis (ALS) patients in Australia, with plans to enroll ALS patients in the U.S. following recent FDA IND clearance. Additional information on the ALS trial may be found on ClinicalTrials.gov (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3VKekJuvwYbtIyNCnGjGYy6nxk4zt0cWSpPDfOGeuU5F437IFPKDG3yrwSFmbLlDPzDvAWsgtPxpad-FUPFH8UERK5cTMsjiQZK-FHexsMmc_W8Tyrl-9Xw3fdo8AiFg\" rel=\"nofollow noopener\" target=\"_blank\" title=\"NCT05882695\">NCT05882695<\/a>).<\/p>\n<p><strong>About SPG302<\/strong><br \/>SPG302 is a once-a-day pill being developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases with the unique ability to restore synapses, the key connections between neurons that allow people to think, plan, remember, and control motor functions. The synaptic regenerative activity of SPG302 represents a first-in-class approach to treating these diseases and has the potential to reverse declines in cognitive, respiratory, and motor function. SPG302 has been granted U.S. FDA Orphan Drug Designation for the treatment of ALS. Additional information on the clinical trials evaluating SPG302 can be found on ClinicalTrials.gov (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3VKekJuvwYbtIyNCnGjGY8JNG0IbB6nKnUWPsJIhMEq792J3KWHQ7d22yoM_0R4xqcuC3359tbFBobQm5USXX0cC-FUz8QbxG-SGf-BSNeTJ3o7-qnghzgrd2pJukah3\" rel=\"nofollow noopener\" target=\"_blank\" title=\"NCT05882695\">NCT05882695<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vS-Y_KNInJmZrdROP-l79J7N0WTDs8v9vnbMVj66VhA9KDItPReQWwEZHQv9AOZ-TYK6yHEfvzgJqomvXJh-XkLJ63KfDajNl32n5ZA8gTE=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"NCT06427668\">NCT06427668<\/a>). SPG302 has received preclinical support from the U.S. National Institutes of Health and the Department of Defense.<\/p>\n<p><strong>About Alzheimer\u2019s Disease<\/strong><br \/>Alzheimer\u2019s Disease is the most common cause of dementia, accounting for ~60-70% of dementia cases worldwide. Loss of synapses occurs very early in Alzheimer\u2019s and is a major driver of progressive impairments in cognition and memory. Currently, there is no cure for AD and medications that are approved for use in AD have only modest and temporary impact on symptoms.<\/p>\n<p><strong>About Spinogenix<\/strong><br \/>Spinogenix is dedicated to developing transformative therapeutics for conditions involving the loss or dysfunction of synapses. Our lead clinical-stage synaptic regenerative drug, SPG302, is a first-in-class therapeutic designed to reverse synapse loss and improve cognitive and motor functions in neurodegenerative and neuropsychiatric diseases such as ALS, Alzheimer\u2019s disease, and schizophrenia. In addition, we are developing a synaptic function therapeutic, SPG601, designed to improve cognitive and other symptoms in Fragile X Syndrome by correcting specific abnormalities in synaptic communication. More information on Spinogenix can be found at www.spinogenix.com or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y1DmZA49CoiHY0HcBCfcWJd4fQYm6Zkj7of_L-AdrkkkAy85P3hqGyGfQs9HJg1irZq0I0cBbP12SWulDKhFdQfZB8BshlPPrdhFOuk4iEs=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.\u00a0<\/p>\n<p><strong>Spinogenix Contact<\/strong><\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tvcsrJIQKaDSeU4vCyXH9AUkpwfjvH1UXW0iVRYF4qQoTyMivg24uFp9XSAd0V7BqpqRSXkkO074OU6wZNlLyee1VtdFIoJSHYB2_C98yMc=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"info@spinogenix.com\">info@spinogenix.com<\/a><\/p>\n<p><strong>Media Contact<\/strong><\/p>\n<p>Kristin Politi, Ph.D.<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4CNIRtVyGfN-fyTp9nwfuIuOIiv5G3_6VaGB21c-qWXhBbWiczH8qP6IVdqOZmc86QJhsvFLI19bV75Yp6XN_gkgpyiXqAEpZwCy_Dm0UMU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"kpoliti@lifescicomms.com\">kpoliti@lifescicomms.com<\/a><br \/>(646) 876-4783<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDRkNTdkMDItNzkzMC00MTc5LTk1YzItNWIzZjZjMDY4ZmM3LTUwMDEyMzc1Ng==\/tiny\/Spinogenix-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer\u2019s disease LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) &#8212; Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that enrollment is now [&#8230;]\n","protected":false},"author":1,"featured_media":57865,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer\u2019s disease L\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-01T12:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Spinogenix-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease\",\"datePublished\":\"2024-08-01T12:04:23+00:00\",\"dateModified\":\"2024-08-01T12:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\",\"name\":\"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-08-01T12:04:23+00:00\",\"dateModified\":\"2024-08-01T12:04:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease","og_description":"SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer\u2019s disease L","og_url":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-08-01T12:04:23+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Spinogenix-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease","datePublished":"2024-08-01T12:04:23+00:00","dateModified":"2024-08-01T12:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/"},"wordCount":650,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/","url":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/","name":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-08-01T12:04:23+00:00","dateModified":"2024-08-01T12:04:23+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/spinogenix-announces-open-enrollment-for-phase-2-study-evaluating-spg302-for-the-treatment-of-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57864"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/57865"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}